Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Investing Activities (2023 - 2025)

CG Oncology (CGON) has disclosed Cash from Investing Activities for 3 consecutive years, with -$75.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 792.39% year-over-year to -$75.5 million, compared with a TTM value of -$245.8 million through Dec 2025, up 18.27%, and an annual FY2025 reading of -$245.8 million, up 18.27% over the prior year.
  • Cash from Investing Activities was -$75.5 million for Q4 2025 at CG Oncology, down from $15.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $103.4 million in Q2 2023 and bottomed at -$307.4 million in Q1 2024.
  • Average Cash from Investing Activities over 3 years is -$55.6 million, with a median of -$17.4 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities skyrocketed 119.83% in 2024, then crashed 792.39% in 2025.
  • Year by year, Cash from Investing Activities stood at $15.5 million in 2023, then decreased by 29.8% to $10.9 million in 2024, then plummeted by 792.39% to -$75.5 million in 2025.
  • Business Quant data shows Cash from Investing Activities for CGON at -$75.5 million in Q4 2025, $15.0 million in Q3 2025, and $1.4 million in Q2 2025.